AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 385
- Registration Number
- NCT00936221
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 119
- Registration Number
- NCT00935662
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 427
- Registration Number
- NCT00935532
- Locations
- 🇯🇵
Research Site, Toyama, Japan
Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT00935467
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With Schizophrenia
Completed
- Conditions
- Quality of Life in Schizophrenia
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2011-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00934726
AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00935025
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Metabolic Syndrome Observation on a Regional Basis
Completed
- Conditions
- Metabolic Syndrome
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT00933010
- Locations
- 🇮🇹
Research, Foligno, Italy
🇮🇹Research Site, Terni, Italy
Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients
Completed
- Conditions
- Dyslipidemias
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2009-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT00931320
Adult Bipolar Mania
Phase 4
Completed
- Conditions
- Acute Mania
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 356
- Registration Number
- NCT00931723
- Locations
- 🇺🇦
Research Site, Vinnitsia, Ukraine
AZD6088 Single Ascending Dose Study
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2009-09-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00931541
- Locations
- 🇬🇧
Research Site, London Bridge, Greater London, United Kingdom